KOE · 216080.KQ
JETEMA, Co., Ltd.
₩5,810-₩110 (-1.86%)
JETEMA, Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.49% below the high.
Loading market information…
KOE · 038290.KQ · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:17 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Macrogen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.04% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Macrogen, Inc.’s forward annual dividend is ₩300 per share, paid annual. The forward yield is 2.76% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Macrogen, Inc.’s next earnings report is currently expected on Nov 18, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Macrogen, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Macrogen, Inc. specializes in offering a wide array of services within genetic research and biotechnology. Their core offerings span various solutions, including whole-genome, clinical, and personalized DNA sequencing, as well as oligonucleotide synthesis, microarray analysis, and the creation of genetically engineered mice. This company was established on June 5, 1997, and its corporate headquarters are situated in Seoul, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| ₩33B+2.81% vs estimate |
| Q2 2024 | Aug 13, 2024 | -₩288 | ₩30.16B-6.03% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩5,810-₩110 (-1.86%)
JETEMA, Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.49% below the high.
₩5,250-₩100 (-1.87%)
EASY BIO,Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.67% below the high.
₩3,000+₩30 (+1.01%)
MedPacto, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.32% below the high.
₩2,790-₩85 (-2.96%)
iNtRON Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.2% below the high.
₩915+₩9 (+0.99%)
Amicogen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.8% below the high.
₩832-₩45 (-5.13%)
CG Invites Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.09% below the high.
₩4,695-₩165 (-3.4%)
Encell Co. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 77.59% below the high.
₩2,670-₩215 (-7.45%)
GeneOne Life Science, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.56% below the high.
